Optimizing First-Line and Sequential Therapy in Advanced NSCLC
Panelists discuss how biomarkers like PD-L1 guide first-line therapy in advanced non-small cell lung cancer (NSCLC), with higher expression favoring PD-1 inhibitors. Other factors like performance status and comorbidities also support their use. Post progression, PD-1 inhibitors are often used alone or in combination for subsequent lines of treatment.
Video content above is prompted by the following:
- What role do biomarkers like PD-L1 play in determining first-line therapy options for advanced NSCLC, and how does level of expression impact initial drug choice?
- What other patient characteristics influence initial treatment choices in advanced NSCLC, and how do they support using PD-1s as first-line options?
- Following disease progression on initial therapy, how frequently are PD-1 inhibitors used alone or in combination for subsequent lines of treatment?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
